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Abstract
Background: Pseudomonas aeruginosa is an opportunistic bacterial pathogen responsible for both acute and
chronic infections in humans. In particular, its ability to form biofilm, on biotic and abiotic surfaces, makes it
particularly resistant to host’s immune defenses and current antibiotic therapies as well. Innovative antimicrobial materials,
like hydrogel, silver salts or nanoparticles have been used to cover new generation catheters with promising
results. Nevertheless, biofilm remains a major health problem. For instance, biofilm produced onto endotracheal
tubes (ETT) of ventilated patients plays a relevant role in the onset of ventilation-associated pneumonia. Most of
our knowledge on Pseudomonas aeruginosa biofilm derives from in vitro studies carried out on abiotic surfaces, such as
polystyrene microplates or plastic materials used for ETT manufacturing. However, these approaches often provide
underestimated results since other parameters, in addition to bacterial features (i.e. shape and material composition of
ETT) might strongly influence biofilm formation.
Results: We used an already established biofilm development assay on medically-relevant foreign devices (CVC catheters)
by a stably transformed bioluminescent (BLI)-Pseudomonas aeruginosa strain, in order to follow up biofilm formation on
ETT by bioluminescence detection. Our results demonstrated that it is possible: i) to monitor BLI-Pseudomonas aeruginosa
biofilm development on ETT pieces in real-time, ii) to evaluate the three-dimensional structure of biofilm directly on ETT,
iii) to assess metabolic behavior and the production of microbial virulence traits of bacteria embedded on ETT-biofilm.
Conclusions: Overall, we were able to standardize a rapid and easy-to-perform in vitro model for real-time monitoring
Pseudomonas aeruginosa biofilm formation directly onto ETT pieces, taking into account not only microbial factors, but
also ETT shape and material. Our study provides a rapid method for future screening and validation of novel antimicrobial
drugs as well as for the evaluation of novel biomaterials employed in the production of new classes of ETT.
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Background
It is known that microbial biofilm frequently forms on
the surface of endotracheal tubes (ETT) implanted in
patients receiving assisted ventilation [1–4]. In particular,
biofilm occurs onto more than 90% of ETT within 7 days
from insertion, since standard cleaning practices are not
able to fully clear bacterial slime [5, 6]. As a consequence,
ETT-associated biofilm increases the risk of upper re-
spiratory tract infections, as well as device occlusion
and wound infections, among other complications [7, 8].
Biofilm on ETT is recognized to be one of the main causes
of ventilator-associated pneumonia (VAP) [9, 10]. The latter
is commonly caused by the opportunistic pathogen Pseudo-
monas aeruginosa (P. aeruginosa) [11]. P. aeruginosa is a
Gram negative bacterium that possesses several virulence
tracts, some of which are cell-associated moieties (like fla-
gella, pili, lectins, alginate/biofilm, lipopolysaccharide) while
some others are secreted (namely proteases, hemolysins,
cytotoxin, pyocyanin, siderophores, exotoxin A, exoenzyme
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S, exoenzyme U, etc.) [12]. Furthermore, P. aeruginosa is
one of the greatest biofilm producers.
Soon after intubation, bacteria can adhere and multiply
on the ETT surface to form biofilm. From there, entry of
opportunistic pathogenic bacteria is facilitated so that the
lower respiratory tract as well as the lung parenchyma are
often involved [2, 11]. Notoriously, biofilm represents a
complex and tightly adherent microbial community, em-
bedded in an abundant matrix of hydrated extracellular
polymeric substance (EPS), primarily composed of poly-
saccharides, proteins, nucleic acids and lipids [13]. From
biofilm, microbial cells detach and easily get access to the
lower airways through ventilator gas flow and aspiration
[2]. Therefore, biofilm on ETT provides a persistent reser-
voir of pathogens likely responsible for VAP [3, 10, 11]. P.
aeruginosa biofilm structure and stability are determined
by at least three different polysaccharides, namely alginate,
Pel and Psl [14, 15]. In particular, alginate is able to
stabilize biofilm structure and to contribute to water re-
tention and nutrients accumulation inside the matrix [16].
Another relevant component of P. aeruginosa biofilm is
extracellular DNA (eDNA), which is known to play a key
role in the onset and growth of P. aeruginosa biofilm,
thanks to its ability to act as a cell to cell interconnection
compound [13, 17, 18] and to be precious nutrient source
for the embedded bacteria [19].
Once established, biofilm can resist to antibiotics and
host immune response [20–23]. New chemical and mech-
anical approaches are currently under study to fight bio-
film formation on ETT. The use of modified ETT (e.g.
cuffed ETT and silver or other nanoparticle-coated ETT)
have been shown to decrease the incidence of VAP in
adults [24, 25]. Nevertheless, biofilm remains a serious
health problem, requiring the development of efficacious
preventive and therapeutic anti-biofilm approaches. In
addition to bacterial factors, a largely underestimated fea-
ture, i.e. the combination of ETT shape and material com-
position, may strongly influence biofilm formation [26].
Indeed, most of our present knowledge on P. aeruginosa
biofilm development onto ETT originates from in vitro
studies on abiotic substrates, such as polystyrene wells or
plastics per se, without taking into account other struc-
tural and three-dimensional parameters.
In the present work, by using a bioluminescent strain of
P. aeruginosa, we describe a rapid and easy-to-perform in
vitro system for real-time monitoring P. aeruginosa bio-
film formation, directly onto ETT. Through this proced-
ure, it was also possible to evaluate the biofilm
three-dimensional structure, the metabolic behaviour and
the expression of microbial virulence traits of bacteria em-
bedded within ETT-biofilm.
Therefore, our innovative approach allows us to study
biofilm formation directly onto medical devices, taking
into account not only microbial factors but also the
combination of ETT shape and material. In our hands,
we believe that such model mimics much more closely
the process of biofilm formation occurring in the clinical
setting.
Methods
Pseudomonas aeruginosa strains
The following strains were used: the bioluminescent P.
aeruginosa (P1242) (BLI-Pseudomonas) and P. aeruginosa
PAO1 (ATCC 15692) (wild type (WT)-Pseudomonas). As
detailed elsewhere, BLI-Pseudomonas expressed the lucif-
erase gene and luciferase substrate under the control of a
constitutive P1 integron promoter [27].
Pseudomonas aeruginosa culture conditions and cell
growth
Bacteria from − 80 °C glycerol stocks were initially
seeded onto Tryptic Soy Agar (TSA) plates and incu-
bated overnight at 37 °C; then, a fresh single colony was
collected, inoculated into 10 ml of Tryptic Soy Broth
(TSB) and cultured overnight at 37 °C. The culture was
then washed and inoculated into fresh medium (TSB
plus 2% sucrose) at a dilution 1:10. To create a bacterial
growth curve, the optical density at 595 nm (OD595) was
determined every 20 min using a spectrophotometer
(Tecan Sunrise™). After each reading, 100 μl were col-
lected and plated onto TSA in order to determine the
number of Colony Forming Units (CFU). For all the ex-
periments, starting bacterial suspension was adjusted at
5 × 104 CFU/ml in TSB with 2% sucrose. To quantify the
bioluminescence emission by BLI-Pseudomonas in the
experimental groups, a calibration curve was generated
in the microtiter plate. In particular, serial dilutions
(starting from 1 × 107/ml) of bacterial suspension in TSB
with 2% sucrose were prepared and 100 μl of each dilu-
tion was seeded in a black transparent-well microtiter
plate. The plate was immediately read by using Victor™
X Light 2030 Luminescence reader (Perkin Elmer).
Endotracheal tube (ETT) pieces preparation
Twenty-four hours before each experiment, a sterile
disposable paediatric endotracheal tube (ETT) (RUSCH
3.0 mm – 5.0 mm) was cut under a biological safety
cabinet (to maintain sterile conditions), in pieces of
0.5 cm length, as previously described by Kucharikova
S. et al., with minor modifications [28] (Additional file 1).
A maximum of 4 ETT pieces were placed into 1.5 ml
microcentrifuge tubes, covered with foetal bovine serum
(FBS) and vortexed. Then, further 100–200 μl of FBS were
added to each tube to completely cover all ETT pieces,
before being incubated at 37 °C overnight in static
conditions.
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Biofilm formation on ETT pieces
In order to allow biofilm formation on ETT pieces, 200 μl
of overnight cultures of BLI-Pseudomonas or WT-Pseudo-
monas (both at 5 × 104/ml) in TSB with 2% sucrose were
seeded in 96 well-plates, containing 1 ETT piece/well,
either in the presence or absence of gentamicin (4 μg/ml);
the plates were then incubated at 37 °C for 90 min (ad-
hesion period). After incubation, the ETT pieces were
washed twice with PBS at room temperature (RT),
transferred to new wells and incubated for 12, 24 or
48 h in fresh TSB with 2% sucrose with or without gen-
tamicin (4 μg/ml) at 37 °C plus 5% CO2. Unless otherwise
specified, every 24 h the culture medium was replaced
with fresh medium with or without gentamicin. After 12,
24 or 48 h of incubation, ETT pieces were washed twice
with PBS at RT and biofilms were analyzed both by our in-
novative method and by a standard methods (see below).
Real-time monitoring of biofilm formation on ETT pieces
by bioluminescence and CFU analysis
After biofilm formation on ETT pieces, as described
above, the bioluminescence was measured by using the
Victor™ X Light 2030 Luminescence reader (Perkin Elmer).
Data is shown as Relative Luminescence Units (RLU).
In selected experiments, the ETT pieces, treated as
above described, were washed twice with PBS at RT, trans-
ferred to a microcentrifuge tubes containing PBS (1 ml),
sonicated for 15 min at 30,000 Hz in a water bath sonica-
tor, then placed on ice, vortexed for 20 s and placed again
on ice. Subsequently, 100 μl of each microbial suspension,
appropriately diluted, were plated onto TSA and incu-
bated for 48 h at 37 °C. After incubation, the CFU were
counted and data was expressed as CFU/ml.
Evaluation of biofilm formation on ETT pieces by
transmitted-illumination confocal microscopy and crystal
violet staining
After the 90 min of adhesion period (T0) and 24 and 48 h
of exposure to BLI-Pseudomonas as above described, the
ETT pieces were washed twice with PBS at RT and fixed
with paraformaldehyde (PFA) for 30 min at 4 °C, washed
twice with PBS and then analyzed by transmitted-illumin-
ation confocal microscopy Nikon LV 150 Confovis Micro-
scope. In selected experiments, after the 12, 24 and 48 h
of exposure to BLI-Pseudomonas as described above, the
ETT pieces were washed twice with PBS at RT, transferred
to new wells and then stained with 2% crystal violet (CV)
to quantify total biofilm mass directly on the ETT. This
was done according with Stepanović’s protocol, with
minor modifications [29]. Prior to OD evaluation, the
ETT pieces were removed from the wells and the OD
were measured on the liquid phase only. The OD values
were measured at 570 nm by using Sunrise™ spectropho-
tometer (Tecan).
Analysis of alive/dead cells embedded in ETT biofilm
To discriminate alive/dead microbial cells directly within
biofilm formed on ETT pieces, after 48 h of exposure to
BLI-Pseudomonas in the presence or absence of gentami-
cin (4 μg/ml), as described above, the ETT pieces were
washed twice with PBS at RT, transferred to new wells
containing 200 μl of PBS and stained by using the “live/
dead imaging kit” (Thermo Fisher Scientific) that employs
propidium iodide (PI) to label dead cells and 5(6)-carboxy-
fluorescein diacetate (CFDA) to label alive cells. The stain-
ing protocol was conducted according to the
Manufacturer’s instruction. After 15 min of incubation at
37 °C, the ETT pieces were washed twice with PBS and
the fluorescence emission (PI excitation/emission: 528/
645; CFDA excitation/emission: 485/528) was analysed
by a multi-well fluorescence plate reader (Synergi HTX,
BIOTEK). The results were expressed as relative fluores-
cence units (RFU). In parallel, microbial bacterial cultures
(used as a control) were grown in planktonic form for 48 h
with or without gentamicin, washed, centrifuged, resus-
pended in fresh medium and stained with the same kit.
Quantification of eDNA and pyoverdine in cell-free
supernatants from ETT biofilm
For the analysis of eDNA and pyoverdine in cell-free
supernatants, after the adhesion period, ETT pieces
were incubated for 24 or 48 h in TSB with 2% su-
crose with or without gentamicin (4 μg/ml). Medium
was never replaced during the incubation period, which
was carried out at 37 °C plus 5% CO2. Then, cell-free
culture supernatants were collected and tested for
eDNA and pyoverdine content. In detail, the ETT pieces
were removed and the supernatants were collected and
centrifuged twice at 10,000 rpm for 15 min in order to re-
move the remaining bacteria. To exclude residual viable
bacteria, 50 μl of the supernatants were seeded onto TSA
plates and incubated for 48 h at 37 °C under aerobic condi-
tions; no bacterial CFU on TSA plates were ever observed.
To quantify eDNA concentration in the cell-free superna-
tants, 100 μl of supernatants were incubated with PI (1 μg/
ml) for 15 min at 37 °C; then, fluorescence emission was
quantified with a multi-well fluorescence plate reader
(Synergi HTX, BIOTEK) (excitation/emission: 528/645).
In parallel, pyoverdine release was quantified in 100 μl
of the same culture supernatants (excitation/emission:
360/460), according to a standard protocol [30]. The
measured amounts of eDNA and pyoverdine were plot-
ted as RFU mean of triplicate samples ± SEM.
Moreover, microbial bacterial cultures (used as a con-
trol) were grown in planktonic form for 24 and 48 h
with or without gentamicin (4 μg/ml) and cell-free su-
pernatants were analysed for the presence of both eDNA
and pyoverdine, as above described.
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Quantification of biofilm on coverslips
To produce biofilm on coverslips, 1 ml of overnight cul-
tures of BLI-Pseudomonas (5 × 104/ml) in TSB with 2%
sucrose were seeded in 6-well-chamber slides containing
coverslips in the presence or absence of gentamicin
(4 μg/ml) and incubated for 24, 48 or 72 h at 37 °C
plus 5% CO2. Every 24 h, the medium was replaced
with fresh medium with or without gentamicin (4 μg/ml).
After 24, 48 or 72 h of incubation, coverslips were washed
twice with PBS at RT, air-dried, transferred to a microscope
slide and analyzed, as previously described [31], with a
Nikon Eclipse 90i imaging system equipped with Nomarski
DIC optics (Nikon Instruments Inc. USA) (40X). Images
were acquired by a DS-2Mv Nikon digital camera and
analysed using the Nikon NISELEMENTS version D3.1
software. The thickness of the biofilm was measured and
expressed in μm.
Biofilm-related genes
After 24 h of exposure to BLI-Pseudomonas in the presence
or absence of gentamicin (4 μg/ml), as described above, the
ETT pieces were washed twice with PBS at RT, transferred
in a microcentrifuge tubes containing PBS (1 ml), sonicated
for 15 min at 30,000 Hz in a water bath sonicator, then
placed on ice, pipetting up and down ten times. Then,
100 μl from each tube as well as of 100 μl of an over-
night fresh culture of BLI-Pseudomonas (both 1 × 106 cells)
were used for DNA extraction by the rapid alkaline lysis
method, as previously described [32]. The lasR-lasI quorum
sensing (QS) genes [33], the lasB, toxA and the algD genes
[34], as well as proC housekeeping gene [35], were deter-
mined by polymerase chain reaction (PCR) performed and
analysed as described previously [36], using primers re-
ported elsewhere [33–35].
Statistical analyses
Statistical analysis was conducted using GraphPad Prism
7.0 software. Data depicted in Figures are the mean ±
standard error (SEM) from replicate samples of 3–7 differ-
ent experiments. Statistical analysis was carried out with
either two-tailed Student’s t-test or one-way ANOVA with
Bonferroni’s post-hoc test. Values of p < 0.05 were consid-
ered significant.
Results
Real-time monitoring of BLI-Pseudomonas biofilm on ETT
To investigate the possibility of real-time monitoring
biofilm formation directly onto ETT pieces, we followed
the bioluminescence emission from each single ETT
piece exposed to BLI-Pseudomonas during a 12, 24 and
48 h incubation period. In parallel, the WT-Pseudomonas
was used as negative control. Box plots in Fig. 1a show that
the bioluminescence signal, expressed as RLU, significantly
increased over the time. The treatment with gentamicin
strongly affected biofilm formation on ETT pieces, at each
time point tested. As expected, no bioluminescence signal
was ever observed when using WT-Pseudomonas (data not
shown). Figure 1b shows the results of representative exper-
iments where groups of twelve samples (treated or not with
gentamicin) were analysed in kinetics for bioluminescence
emission. Each piece was marked with a different
colour, so that it was possible to follow biofilm forma-
tion in each individual ETT piece over time. In selected
experiments, we quantified the CFU (by standard method)
from biofilm grown on ETT pieces, using the same experi-
mental conditions. The results, depicted in Fig. 1c, showed
that the number of CFU had a trend similar to that ob-
served by bioluminescence analysis; nevertheless, the RLU
results seemed to be more accurate in discriminating
kinetic differences between the experimental groups.
Figure 1d shows the kinetics of biofilm formation, assessed
by means of CFU, on ETT pieces treated and untreated
with gentamicin.
Using both tests (i.e. bioluminescence and CFU), no
significant differences were observed between 24 and
48 h, suggesting that, in our experimental conditions, the
maximum of biofilm biomass was achieved after 24 h.
Gentamicin treatment significantly affected biofilm forma-
tion, both in terms of RLU and CFU (Fig. 1). Preliminary
experiments, performed to construct a calibration curve,
indicated that the analytical sensitivity of the biolumines-
cence signal from the BLI-Pseudomonas cells was more
than 1000 bacterial cells (Additional file 2).
Topographic analysis and evaluation of biofilm biomass
on ETT
To further characterize the biofilm structure on ETT, we
performed a topographic analysis (3D mapping) of a 0,
24 and 48 h-old biofilm produced on ETT pieces, by
transmitted-illumination confocal microscopy. The re-
sults show the absence of biofilm at 0 h (Fig. 2a and b).
Moreover, Fig. 2c and e show the tridimensional archi-
tecture of the biofilm after 24 and 48 h of incubation
with BLI-Pseudomonas, respectively. In addition, to bet-
ter evaluate biofilm structure and thickness, a topo-
graphical reconstruction of the surface by means of a
false color scale was carried out (Fig. 2b, d and f ). Fi-
nally, a 3D reconstruction of 24 h and 48 h-old biofilm
could be obtained by means of a mathematical
linearization of the ETT surfaces, as shown in Fig. 2,
C-inset and E-inset.
The biofilm on coverslips was already detectable at
24 h and it kept on growing significantly up to 72 h of
culture, when it reached 65 μm of thickness. No biofilm
was produced on gentamicin-treated coverslip samples
(Additional file 3). Crystal violet staining of 12, 24 and
48 h-old biofilm, directly on ETT pieces, showed a sig-
nificant increase of biofilm mass over time. As expected,
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treatment with gentamicin significantly affected biofilm
formation, being this effect particularly evident after 24
and 48 h (Fig. 3).
Evaluation of both living and dead cells embedded in ETT
biofilm
In order to demonstrate the versatility of our model, we
investigated the metabolic changes in biofilm following
gentamicin treatment, as a prototype of response to dif-
ferent therapies directly onto ETT. In particular, ETT
pieces were incubated for 48 h with BLI-Pseudomonas
either in the presence or in absence of gentamicin, and
then stained with PI and CFDA to discriminate live from
dead cells. As shown in Fig. 4, the addition of gentami-
cin strongly reduced the number of metabolically active
and viable bacteria embedded in the polymer matrix of
biofilm, as assessed by RFU (panel a) and percentage of
alive/dead cells ratio (panel b), respectively. According
to the evidence that the eDNA released from dead cells
remains embedded within biofilm matrix [17], the signal
of gentamicin-treated biofilm dead cells is much higher
than the signal of gentamicin-treated planktonic dead
cells.
Evaluation of P. aeruginosa virulence traits in ETT biofilm
It has been widely demonstrated that eDNA is a relevant
component of P. aeruginosa biofilm, essential for the on-
set and stability of this sessile community [17, 18]. Hence,
we analyzed eDNA directly on cell-free supernatants of
ETT exposed to BLI-Pseudomonas. As shown in Fig. 5a, a
consistent production of eDNA was observed 24 and 48 h
later; moreover, as expected, eDNA production was sig-
nificantly impaired following the gentamicin treatment. A
minimal release of eDNA could be detected only from
24 h-old planktonic cultures.
In our model, we also analyzed pyoverdine release.
Indeed, pyoverdine is a key pigment for in vivo iron
gathering and virulence expression by P. aeruginosa
[37], and thus it contributes to promote the formation
of biofilm [38]. Our results showed that significant levels
Fig. 1 Real-time evaluation of biofilm formation on ETT pieces and CFU counts. Box plots of RLU (a) and of CFU/ml (c) of BLI-Pseudomonas
biofilm on ETT pieces, untreated (white box plots) or treated (grey box plots) with gentamicin after 12, 24 or 48 h of incubation. Mean +/− SEM
of RLU (b) or CFU/ml (d) analysis from 12 different ETT pieces. Circles or squares indicate the ETT pieces untreated or treated with gentamicin,
respectively. Each ETT piece in panel b has a different colour: this allows us to follow the development of biofilm over time. Values of p < 0.05 (*),
p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****) were considered significant
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of pyoverdine were released from 24 and 48 h-old BLI-P-
seudomonas ETT biofilm. As expected, gentamicin treat-
ment markedly reduced pyoverdine release (Fig. 5b). A
basal level of pyoverdine release was detected from plank-
tonic cultures at all testing time points, irrespective of
gentamicin presence.
By analyzing some key genes involved in P. aeruginosa
biofilm formation (such as lasR and lasI, algD, lasB and
toxA) we found that they were all present in ETT-formed
biofilm as well as in planktonic cells (gentamicin-treated
biofilm served as negative control) and likely expressed in
both. proC housekeeping gene was used as internal con-
trol (not shown) (Additional file 4).
Discussion
Despite the numerous improvements in management of
health-care associated infections, bacterial biofilm, often
associated with the use of indwelling medical devices,
remains a major concern. Indeed, once organized in a bio-
film, microorganisms survive, in spite of host immune re-
sponses and antibiotic treatment. Biofilm formation is a
multifactorial phenomenon and it is likely related to the
Fig. 2 Confocal analysis of ETT biofilm. a, c, e: real black and white images acquired by transmitted-illumination confocal microscope of a 0, 24 and 48 h-
old biofilm, respectively. These images result from the multiple acquisitions of several focal planes, which are ultimately combined. b, d, f: topography of
the surface of a 0, 24 and 48 h-old biofilm, respectively, obtained by means of a false color scale. Specifically, the confocal microscope software allows us
to see the differences in sample structure and thickness by assigning different colors to different areas. For each image, its own scale is given on the right
side of the figure. The colored figures are tilted with respect to black and white correspondent images to highlight structure and thickness differences. C-
inset and E-inset: 3D reconstruction of a 24 and 48 h-old biofilm, respectively, obtained by means of a mathematical linearization of the ETT surfaces. The
images shown are representative of 2 independent experiments with the same pattern of results
Fig. 3 Crystal violet staining of ETT biofilm. Mean +/− SEM of biofilm
mass analysed by CV staining (OD570). ETT pieces cultured for 12, 24 and
48 h with BLI-Pseudomonas in the presence (grey columns) or absence
(black columns) of gentamicin were assessed. Values of p < 0.05 (*),
p < 0.001 (***) and p < 0.0001 (****) were considered significant
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production of a resistant EPS coating, to the reduction
of microbial metabolism within the biofilm, and to the
capacity of bacteria to share important drug-resistance
genes [39]. Among numerous devices, ETT are especially
susceptible to biofilm formation. They easily undergo mi-
crobial colonization and biofilm formation on their own
surface, because of the concomitant skin/mucosa barrier
breakdown as well as ETT exposure to respiratory mucus
and blood that may further facilitate bacterial binding to
such abiotic surface [7, 40, 41]. Finally, biofilm formation
on ETT is widely feared since it provides a hidden bacter-
ial reservoir that may delocalize and cause VAP among
mechanically ventilated patients [10].
Most of our current knowledge of P. aeruginosa biofilm
formation on medical devices, such as ETT, derives from
in vitro studies on polystyrene or rough plastic sections
[30, 42, 43]. Such models suffer from a relevant limitation,
i.e. an underestimation of the role played by both device
shape and material of ETT combined. These features, in
addition to bacterial factors, may affect biofilm formation
in vivo. For this reason, here, we describe a rapid and
easy-to-perform in vitro method, which allows for a
real-time evaluation of all the phases of P. aeruginosa
biofilm formation onto a medical device. This method
is designed to mimic, as close as possible, the real-life
conditions, where the combination of microbial virulence
Fig. 4 Quantification of alive/dead cells embedded in ETT biofilm. Relative Fluorescence Units (RFU) mean (a) and percentage (b) of alive (grey)
and dead (black) cells into ETT 48 h-old BLI-Pseudomonas biofilm and planktonic cultures, treated or not with gentamicin. The data shown
are representative of three independent experiments, which provided similar pattern of results
Fig. 5 eDNA and pyoverdine determination in cell-free supernatants from ETT biofilmRFU mean +/− SEM of eDNA (a) and pyoverdine (b)
production in cell-free supernatants of BLI-Pseudomonas biofilm on ETT pieces and planktonic cultures, untreated or treated with gentamicin, after
0, 24 or 48 h of incubation. 1: untreated planktonic cells 2: gentamicin-treated planktonic cells 3: untreated biofilm 4: gentamicin-treated biofilm
***p < 0.001 and *p < 0.05; gentamicin-treated samples vs untreated samples
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factors and device shape and material all play a crucial
role in biofilm formation.
On a previous work, Kucharikova and colleagues [28],
have monitored real-time biofilm formation onto central
venous catheter (CVC) pieces, using a well-established
engineered strain of bioluminescent C. albicans (gLUC59)
[44]. Starting from these data, here we have used an engi-
neered strain of bioluminescent P. aeruginosa (BLI-Pseu-
domonas) to follow up in real-time biofilm formation on
ETT pieces. Although the two models are conceptually
quite similar, the BLI-Pseudomonas employed in this study
offers a substantial advantage: unlike bioluminescent C.
albicans, which needs the exogenous administration of
the specific substrate (coelenterazine) to emit a quantifi-
able luminescence [44], BLI-Pseudomonas can be used
and assessed as it is. BLI-Pseudomonas bears and constitu-
tively expresses both the gene and the substrate necessary
for the bioluminescence emission, as a results of the intro-
duction of a specific lux operon [27, 45]. This peculiarity
renders the system rapid and ready-to-use. The possi-
bility to read the bioluminescence signal without any
additional step simplifies the procedures and improves
both precision and reproducibility. Moreover, the sys-
tem allows multiple measurements in the same sample,
thus allowing kinetic studies where manipulations and
errors are minimized. Another advantage of our
bioluminescence-based assays is that the read out of
each experiment is not dependent on the operator’
skills, further strengthening the validity of this model.
Although our study has been carried out only in vitro,
future studies will focus on real-time monitoring of bio-
film formation onto ETT pieces subcutaneously implanted
in mice, similarly to what has been already done by
Kucharikova and colleagues with CVC pieces [28].
In line with other bioluminescence analysis systems
[28, 31, 46], here we show that quantification of bio-
luminescence by RLU provides data in line with those
obtained by conventional techniques for biofilm quanti-
fication. When compared to techniques such as CFU
and CV determination, our method requires shorter
processing times and it provides more accurate data for
discriminating kinetic differences among different ex-
perimental groups. Moreover, morphological analysis of
the ETT-associated biofilm has been evaluated by confocal
microscopy. Finally, quantification of viable cells can be
easily performed as well. Indeed, by this approach we have
been able to easily discriminate between living and dead
cells embedded in the ETT biofilm, therefore assessing the
viability of biofilm-embedded bacteria, in the presence
and in the absence of gentamicin. Also, the expression of
P. aeruginosa virulence traits (like eDNA and pyoverdine
production as well as quorum sensing genes expression
levels) have been directly measurable in ETT-structured
biofilm. To our knowledge, this in vitro model mimics as
close as possible what may happen in an in vivo situation,
such as in the ventilator-assisted patients.
Conclusions
Overall, we have described an original experimental model
that, by providing a dynamic information on the develop-
ment of a sessile microbial community onto medical de-
vices, may find a rapid and practical application. Studies on
the effectiveness of both new antimicrobial drugs as well as
novel biomaterials, useful for designing and manufacturing
innovative medical devices, may strongly benefit from such
method. Therefore, the present model may find successful
application not only in vitro but also in clinical studies.
Additional files
Additional file 1: Preparation of paediatric ETT pieces. A sterile
disposable paediatric endotracheal tube (ETT) (RUSCH 3.0 mm – 5.0 mm)
was cut in pieces of 0.5 cm length, using a biological safety cabinet to
ensure sterile conditions. (TIF 4704 kb)
Additional file 2: Calibration curve of BLI-Pseudomonas bioluminescence
detection. Increasing numbers of BLI-Pseudomonas cells grown in TSB with
2% sucrose at 37 °C were analysed for bioluminescence emission by using
luminometer. (PDF 80 kb)
Additional file 3: Evaluation of BLI-Pseudomonas biofilm on coverslips.
The data represent the mean +/− SEM of BLI-Pseudomonas biofilm
thickness (expressed in μm) on five different fields of each coverslip,
untreated (black columns) or treated (grey columns) with gentamicin,
after 24, 48 or 72 h of incubation. ***p < 0.001; 24 h-biofilm vs 72 h-
biofilm ****p < 0.0001; gentamicin-treated biofilm vs untreated biofilm.
(TIF 1096 kb)
Additional file 4: Analysis of biofilm-related genes. BLI-Pseudomonas
quorum sensing genes (lasR/lasI, lasB, toxA, algD) in a 24 h-old biofilm formed
on ETT pieces and in the planktonic cells are shown. Lanes show the bands of
each gene, according to the length of fragments expected, detected by gel
analysis: lasR: 725 bp; lasI: 605 bp; lasB 300 bp, toxA 352 bp and algD 1310 bp
(L= ladder). Gentamicin-treated biofilm served as control. (PDF 50 kb)
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